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Abstract
Introduction:  The  pancreas  is  a  rare  metastization  site  for  renal  cell  carcinoma  (RCC);  this  paper
reports a  rare  presentation  of  metastatic  RCC,  of  obstructive  jaundice  secondary  to  a  solitary
synchronous  pancreatic  metastasis;  the  authors  review  the  existing  literature  on  pancreatic
metastization  of  RCC  in  what  concerns  etiopathogenesis,  clinics  and  therapeutic  options.
Clinical case:  A  53-year-old  man  was  referenced  to  consultation  for  complains  of  weakness,
dyspepsia,  back  pain,  choluria,  weight  loss  and  jaundice;  image  exams  revealed  a  single  lesion
on the  head  of  the  pancreas  and  a  tumour  in  the  left  kidney;  after  elective  pancreatico-
duodenectomy  and  radical  nephrectomy,  histology  revealed  a  RCC,  and  a  metastatic  lesion
with endoluminal  growth  in  Wirsung  duct;  the  follow-up  was  uneventful  with  no  evidence  of
recurrence  at  6  months.
Discussion:  Pancreatic  metastization  of  RCC  tend  to  occur  many  years  after  nephrectomy;  com-
puterize tomography  imaging  is  the  method  of  choice  for  its  characterization;  the  R0  resection
provide the  longest  disease-free  survival  possible;  any  patient  with  solitary  metastatic  RCC  in
the pancreas  should  be  a  candidate  for  complete  surgical  excision  if  technically  feasible,  for
palliation  and  prognostic  reasons.
© 2016  Associac¸a˜o  Portuguesa  de  Urologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an  open
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/access article  under  the  CC  
4.0/).∗ Corresponding author.
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Icterícia  obstrutiva  como  apresentac¸ão rara  de  carcinoma  de  células  renais
metastizado  --  Caso  clínico  e  revisão  da  literatura
Resumo
Introduc¸ão:  A  metastizac¸ão  pancreática  do  carcinoma  de  células  renais  (CCR)  é  rara;  Este  artigo
relata um  caso  clinico  de  CCR  com  apresentac¸ão  clínica  de  icterícia  obstrutiva  secundária  a
metastizac¸ão pancreática  solitária  e  síncrona,  e  realiza  uma  revisão  da  literatura  existente
sobre metastizac¸ão  pancreática  do  CCR,  no  que  concerne  à  etiopatogenia,  clínica  e  terapêutica.
Caso clínico: Homem,  de  53  anos,  com  um  quadro  clínico  de  astenia,  dispepsia,  lombalgia,
colúria, perda  ponderal  e  ictericia.  Imagiologicamente  identiﬁcou-se  uma  lesão  única  na
cabec¸a do  pâncreas  e  uma  lesão  neoformativa  no  rim  esquerdo.  Após  duodenopancreatecto-
mia e  nefrectomia  radical,  o  estudo  histopatológico  revelou  um  CCR  e  uma  lesão  pancreática
metastática,  com  crescimento  endoluminal  do  canal  de  Wirsung.  O  seguimento  decorreu  sem
intercorrências  ou  evidência  de  recorrência  aos  6  meses  de  pós-operatório.
Discussão:  A  metastizac¸ão  pancreática  do  CCR  tende  a  ocorrer  vários  anos  após  nefrectomia;  a
tomograﬁa  computadorizada  é  o  método  de  escolha  para  o  estudo  imagiológico;  a  única  opc¸ão
terapêutica  curativa  é  a  excisão  cirúrgica;  um  doente  com  metastizac¸ão  pancreática  isolada  de
CCR deve  ser  candidato  a  metastectomia  completa  no  sentido  de  aumentar  a  sobrevida  livre
de doenc¸a.
© 2016  Associac¸a˜o  Portuguesa  de  Urologia.  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Este e´  um
artigo Open  Access  sob  uma  licenc¸a  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Renal  cell  carcinoma  (RCC)  is  the  third  most  frequent
genitourinary  malignancy.1 It  is  estimated  that  25--33%
of  patients  with  RCC  have  metastases  at  presentation.2--5
RCC  has  the  potential  to  metastasize  to  almost  any  site.6
Although  the  pancreas  is  not  a  common  site  of  metasta-
sis  from  RCC,7 it  is  one  of  the  few  from  which  metastatic
tumours  can  occur,  accounting  for  2%  of  pancreatic  tumours
removed  in  sizable  series  of  operations.2
The  authors  report  a  case  of  a  53-years-old  man  with
a  rare  clinical  presentation  of  metastatic  RCC,  of  obstruc-
tive  jaundice  secondary  to  a  solitary  synchronous  pancreatic
metastasis.
Clinical case
A  53-year-old  man  was  referenced  to  consultation  for  com-
plaints  of  weakness,  dyspepsia,  back  pain,  choluria  and
weight  loss  (10  kg  in  1  month).  On  clinical  examination  he
was  icteric.  Abdominal  examination  was  unremarkable.  By
persistence  of  pain  and  jaundice  the  patient  was  sent  to  the
emergency  room  for  detailed  imaging,  including  abdominal
computerized  tomography  (CT),  and  blood  work.
Laboratory  investigation  on  admission  was:  Haemoglobin
10.0  g/dL,  leucocytes  3.80  ×  109/L,  urea  18  mg/dL,  cre-
atinine  0.86  mg/dL,  total  bilirubin  12.46  mg/dL,  direct
bilirubin  6.29  mg/dL,  AST  70  U/L,  ALT  128  U/L,  GGT  894  U/L,
alkaline  phosphatase  1085  U/L,  pancreatic  amylase  730  U/L
and  PCR  48.2  mg/L.Abdominal  CT  scan  (Fig.  1)  revealed:  a  solid  lesion  on
the  head  of  the  pancreas,  with  diameters  of  30  mm  ×  30  mm
and  lobulated  limits,  the  lesion  was  most  pronounced  in
the  early  arterial  phases  of  enhancement,  conditioned
1
d
etenosis  of  the  intrapancreatic  portion  of  the  bile  duct,  and
ilatation  of  Wirsung’s  channel  and  main  bile  duct;  Multiple
denopathies  larger  than  1 cm  of  diameter;  a  large  solid
ass  in  the  left  kidney  interesting  the  middle  and  lower
hirds  with  9  cm  ×  7  cm  ×  6.5  cm  diameters,  peripheral
nhancement  and  extensive  central  necrotic  area,  without
vidence  of  locoregional  extension  or  venous  thrombosis.
Endoscopic  retrograde  cholangiopancreatography  (Fig.  2)
evealed  dilatation  of  main  biliary  duct,  and  a  transendo-
copic  sphincterotomy  and  placement  of  a biliary  stent
10  Fr,  9  cm)  were  performed.  Abdominal  magnetic  reso-
ance  (MRI)  and  cholangio-MRI  described  the  pancreatic
esion  as  discretely  hypointense  on  T1  and  discretely  hyper-
ntense  on  T2,  with  enhancement  in  the  early  phase  after
adolinium  injection  and  gradual  attenuation  in  the  later
equences.
The  patient  underwent  elective  pancreaticoduodenec-
omy  and  left  radical  nephrectomy  (plus  splenectomy,
ymphadenectomy  and  cholecystectomy).
Histology  and  immunohistochemistry  studies  revealed  a
CC,  clear  cell  variant,  predominantly  Fuhrman  grade  2,
ith  perirenal  fat  inﬁltration  and  vascular  invasion  (Fig.  3);
 lesion  compatible  to  metastization  of  the  described  kid-
ey  neoplasia  was  identiﬁed  in  the  pancreas  (CK7−, CK20−,
D10+),  with  involvement  of  peripancreatic  adipose  tissue,
mpulla  of  Vater,  duodenum,  and  endoluminal  growth  in
irsung  duct  (Fig.  4).  The  surgical  margins  were  free  of
umour  and  no  metastases  were  found  in  the  regional  lymph
odes  (pT3aN0M1).
The  patient  stayed  4  days  in  the  intensive  care  unit  due
o  haemodynamic  instability  and  the  total  clinical  stay  was
0  days.
The  patient  had  to  be  treated  for  postoperative  insulin
ependent  diabetes.  The  follow-up  was  uneventful  with  no
vidence  of  recurrence  at  6  months.
70  P.M.  Baltazar  et  al.
Fig.  1  Contrast-enhanced  abdominal  CT  --  images  of  the  lesion  in  the  head  of  the  pancreas  --  hipervascular  well  delineated  lesion
on the  head  of  the  pancreas  --  (a)  axial  and  (b)  coronal.
Fig.  2  Endoscopic  retrograde  cholangiopancreatography  --
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Fig.  3  Histology  of  the  resected  renal  cell  carcinoma  showing
the characteristic  ﬁndings  of  large  clear  cells.  The  cells  are  in  a
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ehe obstruction  (arrow)  and  marked  dilatation  of  main  bile  duct
arrowhead).
iscussion
ancreatic  metastasis  is  a  rarity  accounting  for  only  2--5%  of
ll  pancreatic  malignancies.6,8 The  most  frequent  places  for
CC  metastasis  are:  the  lungs  (50--60%),  bones  (30--40%),
iver  (30--40%),  suprarenals  and  brain  (5%).9 The  incidence
f  metastasis  from  primary  renal  cell  carcinoma  to  pancreas
anges  from  0.25%  to  3%  of  all  metastatic  RCC.8,10,11 How-
ver  RCC  is  the  most  common  primary  tumour  leading  to
olitary  pancreatic  metastasis,11 these  are  usually  detected
any  years  after  nephrectomy,  ranging  from  6  to  8  years.10
hompson  and  Heffess12 in  a  comprehensive  review  of  the
iterature  examined  the  clinicopathological  features  and
rognosis  for  109  patients  and  reported  that  the  interval
etween  the  initial  nephrectomy  and  the  presentation  of
he  metastasis  averaged  14.6  years  (range,  1 month  to  32.7
ears).  Usually  it  coexists  with  metastases  of  the  lungs,
l
p
i
orabecular  arrangement  and  feature  clear  cytoplasm  and  slight
uclear  variability;  H&E  400×.
rain,  or  bones,  and  when  it  is  solitary  to  the  pancreas,  it  is
istributed  equally  to  all  parts  of  it  (head,  body,  and  tail).13
The  mode  of  spread  of  renal  cell  carcinoma  to  the  pan-
reas  is  controversial,  it  may  occur  by  haematogenous  or
ymphatic  dissemination,  the  direct  spread  to  the  pan-
reas  is  not  thought  to  occur.14,15 Haematogenous  spread
ay  occur  along  the  draining  collateral  veins  of  a  hyper-
ascular  renal  tumour  with  or  without  associated  renal
ein  thrombosis.11,16 Lymphogenous  spread  may  occur  via
etrograde  lymph  ﬂow  through  lymphatic  routes  from  the
ead  of  the  pancreas  to  the  dorsal  side  of  the  renal
rtery.16,17 According  to  Sellner  et  al.,18 local  lymphogenous
r  local  venous  spread  through  abnormal  lymphatic  or
enous  communications  between  the  RCC  and  the  pancreas19
annot  play  an  important  role,  because  this  would  fail  to
xplain  the  lack  of  relationship  between  the  site  of  iso-
ated  pancreatic  metastases  and  the  side  affected  by  the
rimary  tumour:  i.e.,  the  left  or  right  kidney.  The  local-
zation  anywhere  in  the  pancreas  irrespective  of  the  site
f  the  RCC  argues,  instead,  in  favour  of  a  haematogenous
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pFig.  4  (a)  Intrapancreatic  metastasis  from  renal  cell  carcino
of the  Wirsung  duct  shows  no  cellular  atypia;  H&E  40×.
systemic  spread.  However,  a  systemic  spread  would  not
explain  the  discrepancy  between  the  relative  frequency  of
multiple  pancreatic  metastases  and  the  absence  of  metas-
tases  to  other  organs.  The  most  likely  explanation  for  this
unique  behaviour  of  isolated  pancreatic  metastases  would
seem  to  lie  in  the  special  biology  of  the  tumour.  The  high
afﬁnity  of  some  renal  cancer  cells  for  the  parenchyma  of
the  pancreas  is  supported  by  some  reports  of  metachronous
late  metastases  which  again  occurred  solely  in  the  residual
pancreas.19
In  2006,  Sellner  et  al.18 identiﬁed  236  cases  of  isolated
pancreatic  metastasis  of  RCC,  either  asymptomatic  in  35%
of  the  cases,  or  presenting  with  abdominal  pain  (20%),
GI  bleeding  (20%),  obstructive  jaundice  (9%),  weight  loss
(9%),  pancreatitis  and  diabetes  (3%  each),  and  pancreatic
exocrine/endocrine  dysfunction.  Isolated  pancreatic  metas-
tases  are  often  found  with  routine  surveillance  imaging  for
primary  lesions  or  as  an  incidental  ﬁnding  on  imaging.6
Symptoms  are  tumour  diameter-dependent,  more  frequent
in  those  with  more  than  45  mm.10 The  lesions  can  be  multi-
focal  in  approximately  30%  of  patients  and  are  resectable  in
approximately  80%  of  cases.20
The  radiologic  features  of  metastatic  RCC  lesions  closely
resemble  the  appearance  of  primary  RCC.11 CT  imaging
shows  lesions  that  are  most  pronounced  in  the  early  arte-
rial  phases  of  enhancement,  which  hyperenhancing  reﬂects
the  hypervascular  nature  of  this  tumours.6,11 This  feature
aids  in  detecting  RCC  as  well  as  distinguishing  it  from  pri-
mary  adenocarcinoma  of  the  pancreas,  which  is  typically
hypovascular  and  appears  nonenhancing  on  CT  imaging.11
In  the  case  presented,  imagological  evaluation  demon-
strated  a  typical  well  deﬁned  lesion,  with  characteristic
hypervascularity  manifested  by  contrast  enhancement.  The
most  common  type  RCC  metastasis,  reported  in  50--73%
of  cases,  is  that  of  a  solitary,  localized,  encapsulated,
well-deﬁned  mass.  A  second  pattern  of  multiple  pancre-
atic  lesions  has  been  reported  in  5--10%  of  cases  and  a
third  pattern  of  diffuse  metastatic  inﬁltration  causing  gen-
eralized  enlargement  of  the  organ  in  15--44%  of  cases.6 Of
note,  pancreatic  neuroendocrine  tumours  are  also  hyper-
vascular  and  contrast  avid  on  cross  sectional  imaging,  such
that  distinguishing  them  from  RCC  metastases  to  the  pan-
creas  can  be  difﬁcult.21 On  MRI,  pancreatic  lesions  typically
appear  hypointense,  compared  with  normal  gland  tissue  on
e
h
db)  Endoluminal  growth  in  Wirsung  duct.  The  lining  epithelium
nenhanced  T1  weighted  images,  both  with  and  without  fat
aturation.3 Following  intravenous  contrast  injection,  homo-
eneous  enhancement  is  typically  demonstrated  in  smaller
esions  and  rim  enhancement  in  larger  ones.3 On  T2  weighted
mages,  the  lesions  are  slightly  heterogeneous  and  moder-
tely  hyperintense.19 Hypointense  nodules  are  sometimes
isible  on  T2  weighted  images,  especially  in  the  diffusely
nlarged  type.19 Diffusion  weighted  imaging  was  recently
ncluded  in  the  standard  MRI  protocol;  metastatic  lesions
ypically  also  show  a  hyperintensity  signal  in  sequences  with
igh  b-values  (700--1000).19
On  endoscopic  ultrasound  (EUS)  pancreatic  metastases
ppear  as  solid  intraparenchymal  space-occupying  lesions
ith  an  internal  structure  that  is  much  more  hypoechoic
han  the  normal  pancreatic  tissue,  or  isoechoic.  These
esions  are  homogeneous,  round,  well  circumscribed  and
ssociated  with  enhancement  through  transmission  of  the
ltrasonic  beam.19 At  power  Doppler  or  colour  Doppler
valuation  and  with  ultrasound  contrast  agent,  metastatic
ancreatic  tumours  from  RCC  are  hypervascular.19 The  clin-
cal  features  and  ﬁndings  on  imaging  tests  often  do  not
dequately  distinguish  the  nature  of  the  injury,  in  this  sense
US-guided  biopsy  can  obtain  material  for  cytology  and  in
ome  cases  immunocytochemistry  techniques  that  allow  us
o  have  a  more  accurate  diagnosis,22 especially  in  the  case  of
nresectable  lesions,  although  it  is  also  difﬁcult  to  diagnose
rimary  or  metastatic  RCC  in  small  biopsies  because  of  the
ide  variety  of  histologic  appearance,10 and  also  should  be
aken  into  account  the  risk  of  bleeding,  which  is  increased
ue  to  the  high  vascularity  of  the  tumour.6
Although  metastasis  to  the  pancreas  is  most  com-
only  associated  with  disseminated  systemic  disease,  RCC
ypically  spreads  to  the  pancreas  as  an  isolated  lesion,
ften  making  it  amenable  to  surgical  treatment.21 Cur-
ently,  management  depends  on  the  general  condition  of
he  patient,  the  extent  and  location  of  the  lesion,  and
he  concurrent  metastases  at  other  sites.  In  the  case
f  duodenum  metastasis  procedures  from  classic  pancre-
ticoduodenectomy  (Whipple  procedure)  to  interventional
mbolization  have  been  reported.6 Surgical  resection  of
rimary  RCC  and  metastatic  deposits  remains  the  most
ffective  treatment10 since  chemotherapy,  radiotherapy  and
ormonal  therapy  have  proven  ineffective.10 Surgical  proce-
ures  vary  according  to  the  site  and  the  extent  of  the  lesion,
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12  
ncluding  distal  pancreatectomy,  cephalic  pancreaticoduo-
enectomy  or  tumour  enucleation.22
The  outcome  of  isolated  pancreatic  RCC  metastasis  is
learly  more  favourable  with  a  mean  5-years  survival  ran-
ing  from  43%  to  88%.10 In  a  systematic  review  of  more  than
00  patients  with  RCC  pancreatic  metastasis,  Tanis  et  al.23
ound  that  long  disease-free  interval  after  resection  of  pri-
ary  tumour,  a  single,  asymptomatic  metastatic  deposit
ith  central  necrosis  and  complete  excision  of  the  secondary
esion  are  associated  with  good  prognosis.  In  addition,  other
uthors  found  that  synchronous  had  worse  prognosis  when
ompared  to  metachronous  solitary  metastasis.10 Although
he  5-year  survival  rate  of  untreated  pancreatic  metastatic
atients  is  <13%,  the  outcome  of  surgical  resection  of  RCC
ancreatic  metastasis  is  even  superior  to  surgical  resection
f  primary  pancreatic  adenocarcinoma  or  to  treatment  of
solated  pancreatic  metastases  from  neoplasms  other  than
CC.11 Approximately  2--6%  of  patients  with  metastatic
CC  present  with  isolated  metastatic  lesions  amenable  to
urgical  resection.11 Surgical  resection  of  metastatic  dis-
ase  limited  to  the  pancreas  has  a  5-year  survival  rate  of
9--53%1,11,17 and  5-year  disease-free  survival  rate  of  5--23%.1
he  largest  single  centre  series  of  pancreatic  resection  for
CC  metastasis  reported  a  great  5-year  survival  beneﬁt  after
urgical  resection  compared  with  conservative  treatment  of
nresectable  disease  (53%  vs  26%).24 Radical  lymph  node
issection  is  not  necessary,  as  peripancreatic  lymph  node
nvolvement  is  uncommon,  which  may  be  one  of  the  fac-
ors  that  explain  the  favourable  outcomes  achieved  with
urgery.11
Chemotherapy  and  radiotherapy  have  generally  proved
o  be  ineffective  for  primary  RCC  or  metastatic  disease.
espite  promising  results  with  immunotherapy  using  IL-2,  a
omplete  response  occurred  in  less  than  15%  and  was  rarely
urable,  emphasizing  that  complete  resection  of  the  pri-
ary  and  the  metastatic  lesions  whenever  possible  is  the
est  treatment.24 In  recent  years,  with  the  advent  of  target
herapies,  the  prognosis  of  patients  with  metastatic  RCC  has
mproved.6 However,  in  the  absence  of  dramatic  results,  sur-
ical  excisions  of  isolated  metastasis  continue  to  play  a role
n  the  treatment  of  metastatic  RCC.6
We  opted  not  to  perform  EUS  ﬁne  needle  aspiration
efore  surgery  because  negative  results  do  not  change  the
reviously  established  surgical  strategy  due  to  low  sensitiv-
ty  of  this  technique.
In conclusion,  solitary  pancreatic  metastasis  from  RCC  is
 rare  pancreatic  tumour  and  it  is  very  difﬁcult  to  differenti-
te  it  from  pancreatic  adenocarcinoma.  The  R0  resection  is
he  best  approach  available  to  provide  the  patient  with  the
ongest  disease-free  survival  possible,  as  described  in  the  lit-
rature  reviewed,  and  any  patient  with  solitary  metastatic
CC  in  the  pancreas  should  be  a  candidate  for  complete  sur-
ical  excision,  if  medically  and  technically  feasible,  both  for
alliation  and  prognostic  reasons,  as  it  appears  to  prolong
isease-free  survival.
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